HIGHLIGHTS
- who: Sodium-glucose cotransporter- and colleagues from the Department of Life Sciences, School of Sciences, European University Cyprus, Nicosia, Cyprus Massachusetts College of Pharmacy and Health Sciences, Worcester Campus: Worcester, MA, USA have published the research work: Journal of Nephropathology, in the Journal: (JOURNAL) of 12/Dec/2022
- what: The results of this study have shown that dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, reduced the urine to creatine ratio by 26% compared to the control group that received the placebo.
- how: The results of this study clearly show that the use of . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.